Cyclopharm (ASX:CYC) shareholders should be worried about its cash burn. For the purpose of this article, we define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow) On balance, we think it's mildly positive the company trimmed its Cash burn by 6.2% over the last twelve months, and operating revenue was up by 13% too.